144 related articles for article (PubMed ID: 20130784)
1. OXavidin for tissue targeting biotinylated therapeutics.
De Santis R; Albertoni C; Rosi A; Leoni B; Petronzelli F; D'Alessio V; Nucera E; Salvatori G; Paganelli G; Verdoliva A; Carminati P; Nuzzolo CA
J Biomed Biotechnol; 2009; 2009():921434. PubMed ID: 20130784
[TBL] [Abstract][Full Text] [Related]
2. AvidinOX™ for tissue targeted delivery of biotinylated cells.
Nucera E; Nicoletti C; Chiapparino C; Pacello ML; D'Alessio V; Musarò A; De Santis R
Int J Immunopathol Pharmacol; 2012; 25(1):239-46. PubMed ID: 22507336
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and biological characterization of a new oxidized avidin with enhanced tissue binding properties.
Verdoliva A; Bellofiore P; Rivieccio V; Catello S; Colombo M; Albertoni C; Rosi A; Leoni B; Anastasi AM; De Santis R
J Biol Chem; 2010 Mar; 285(12):9090-9. PubMed ID: 20100839
[TBL] [Abstract][Full Text] [Related]
4. Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin.
Wilbur DS; Hamlin DK; Vessella RL; Stray JE; Buhler KR; Stayton PS; Klumb LA; Pathare PM; Weerawarna SA
Bioconjug Chem; 1996; 7(6):689-702. PubMed ID: 8950488
[TBL] [Abstract][Full Text] [Related]
5. Avidin-biotin technology in targeted therapy.
Lesch HP; Kaikkonen MU; Pikkarainen JT; Ylä-Herttuala S
Expert Opin Drug Deliv; 2010 May; 7(5):551-64. PubMed ID: 20233034
[TBL] [Abstract][Full Text] [Related]
6. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease).
Jeong Lee H; Pardridge WM
J Drug Target; 2000; 8(6):413-24. PubMed ID: 11328667
[TBL] [Abstract][Full Text] [Related]
7. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase.
Yao Z; Zhang M; Kobayashi H; Sakahara H; Nakada H; Yamashina I; Konishi J
J Nucl Med; 1995 May; 36(5):837-41. PubMed ID: 7738661
[TBL] [Abstract][Full Text] [Related]
8. Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector.
Campos SK; Parrott MB; Barry MA
Mol Ther; 2004 Jun; 9(6):942-54. PubMed ID: 15194061
[TBL] [Abstract][Full Text] [Related]
9. A novel intravascular drug delivery method using endothelial biotinylation and avidin-biotin binding.
Hoya K; Guterman LR; Miskolczi L; Hopkins LN
Drug Deliv; 2001; 8(4):215-22. PubMed ID: 11757779
[TBL] [Abstract][Full Text] [Related]
10. Ligand exchange between proteins. Exchange of biotin and biotin derivatives between avidin and streptavidin.
Pazy Y; Kulik T; Bayer EA; Wilchek M; Livnah O
J Biol Chem; 2002 Aug; 277(34):30892-900. PubMed ID: 12055191
[TBL] [Abstract][Full Text] [Related]
11. Chemical linkage to injected tissues is a distinctive property of oxidized avidin.
De Santis R; Anastasi AM; Pelliccia A; Rosi A; Albertoni C; Verdoliva A; Petronzelli F; D'Alessio V; Serani S; Nuzzolo CA
PLoS One; 2011; 6(6):e21075. PubMed ID: 21701578
[TBL] [Abstract][Full Text] [Related]
12. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization.
Casalini P; Luison E; Ménard S; Colnaghi MI; Paganelli G; Canevari S
J Nucl Med; 1997 Sep; 38(9):1378-81. PubMed ID: 9293791
[TBL] [Abstract][Full Text] [Related]
13. Intravenous avidin chase improved localization of radiolabeled streptavidin in intraperitoneal xenograft pretargeted with biotinylated antibody.
Zhang M; Sakahara H; Yao Z; Saga T; Nakamoto Y; Sato N; Nakada H; Yamashina I; Konishi J
Nucl Med Biol; 1997 Jan; 24(1):61-4. PubMed ID: 9080476
[TBL] [Abstract][Full Text] [Related]
14. AvidinOX for highly efficient tissue-pretargeted radionuclide therapy.
De Santis R; Leoni B; Rosi A; Albertoni C; Forni G; Cojoca R; Iezzi M; Musiani P; Paganelli G; Chinol M; Carminati P
Cancer Biother Radiopharm; 2010 Apr; 25(2):143-8. PubMed ID: 20423226
[TBL] [Abstract][Full Text] [Related]
15. EGF receptor targeted tumor imaging with biotin-PEG-EGF linked to (99m)Tc-HYNIC labeled avidin and streptavidin.
Jung KH; Park JW; Paik JY; Quach CH; Choe YS; Lee KH
Nucl Med Biol; 2012 Nov; 39(8):1122-7. PubMed ID: 22819251
[TBL] [Abstract][Full Text] [Related]
16. Artificial metalloenzymes based on the biotin-avidin technology: enantioselective catalysis and beyond.
Ward TR
Acc Chem Res; 2011 Jan; 44(1):47-57. PubMed ID: 20949947
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha.
Moro M; Pelagi M; Fulci G; Paganelli G; Dellabona P; Casorati G; Siccardi AG; Corti A
Cancer Res; 1997 May; 57(10):1922-8. PubMed ID: 9157986
[TBL] [Abstract][Full Text] [Related]
18. Three-dimensional structures of avidin and the avidin-biotin complex.
Livnah O; Bayer EA; Wilchek M; Sussman JL
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5076-80. PubMed ID: 8506353
[TBL] [Abstract][Full Text] [Related]
19. Tissue distribution of avidin and streptavidin injected to mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin.
Schechter B; Silberman R; Arnon R; Wilchek M
Eur J Biochem; 1990 Apr; 189(2):327-31. PubMed ID: 2186907
[TBL] [Abstract][Full Text] [Related]
20. Colloidal gold/streptavidin methods.
Oliver C
Methods Mol Biol; 2010; 588():375-80. PubMed ID: 20012851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
